reports
- Sean Conroy
Sareum Holdings - New funding extends runway to Phase II
Sareum Holdings has announced the completion of a £2.4m private placement and receipt of another A$1.9m (c £1m) in R&D tax credits from Australian authorities, related to the Phase I clinical trial for its lead asset SDC-1801, a next-generation TYK2/JAK1 kinase inhibitor. Management expects the combined funds to support preparatory activities, including longer-term toxicology studies, as the candidate advances towards Phase II trials in psoriasis patients. As a reminder, the company had presente...
Hybridan Research 17/09/2024 - Sareum Holdings: First patent protectin...
Sareum announces it has received a Notice of Allowance from the China National Intellectual Property Administration for Crystalline Forms of SDC- 1801. This is the first patent protecting these crystalline forms in any territory and it’s likely that Japan, the US and European territories will follow. This Chinese Patent is expected to be granted by the end of 2024 and will provide significant protection on several crystalline forms of SDC-1801 and in the method of their application. It builds ...
Hybridan Small Cap Feast - 16 September 2024
16th September 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: Vector Capital (VCAP.L) has delisted from AIM What’s baking in the oven? Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email with “unsubscribe me”. Hybridan Chefs Banquet Buffet*** Acuity...
- Emily Liu
Hybridan Research 02/09/2024 - Sareum Holdings: US patent allowance fo...
Sareum today announced that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent on SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases. The US patent, application number US2021387981, will offer substantial protection on the chemical structure of SDC-1801 and an analogue (a compound that is not identical but similar to the chemical structure of 1801), their use in treating inf...
- Emily Liu
Hybridan Small Cap Feast - 2 September 2024
2nd September 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: St Mark Homes (AQSE: SMAP) has delisted from the AQSE Growth Market. East Imperial Plc (EISB.L) has delisted from the Main Market. ReNeuron Group (RENE.L) has delisted from AIM. Infrastructure India Plc (IIP.L) has delisted from AI...
- Emily Liu
Hybridan Small Cap Feast 10 July 2024
Dish of the day Admissions: Delistings: Gresham Technologies (GHT.L) has delisted from AIM Partway Group (PTY.L) delisted from the Main market yesterday What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to continue to make financial progress on its “Bisie North Tin Project”. The Company’s first day of trading on AIM is exp...
- Emily Liu
Hybridan Small Cap Feast - 02/07/24 - Sareum Holdings: Positive topli...
Sareum announced positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases. Sareum believes that dual TYK2/JAK1 inhibition offers the potential for increased efficacy in psoriasis, compared with existing approved oral therapies. The results are summarised as follows: • Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achie...
- Sean Conroy
Sareum Holdings - SDC-1801 records positive Phase Ia data
Sareum Holdings has announced positive top-line data from the Phase Ia clinical trial for SDC-1801, its lead asset, a novel TYK2/JAK1 inhibitor targeting autoimmune conditions. The results, which include data from the multiple ascending dose (MAD) arm, reiterate the drug-supportive safety profile and once-daily dosing potential, complementing the preliminary data released in February 2024. Notably, no significant change in serum creatinine levels (which tends to affect kidney function) was obser...
Hybridan Small Cap Feast - 1 July 2024
1 July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: Delistings: San Leon Energy (SLE.L) has delisted from AIM Gensource Potash Corporation (GSP.L) has delisted from AIM What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 19 June 2024: IntelliAM, an artificial intelligence c...
Hybridan Small Cap Feast - 23 April 2024
23rd April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: Bidstack Group (BIDS.L) has left the AIM market What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to ...
Hybridan Small Cap Feast - 16/04/2024
16th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radical Limited for...
Hybridan Small Cap Feast - 10 April 2024
10th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated propositio...
Hybridan Small Cap Feast - 05 Apr 24
5th April 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objecti...
- Sean Conroy
Sareum Holdings - A decisive period ahead for SDC-1801
Sareum Holdings’ H124 results highlighted the company’s swift progress for lead asset SDC-1801, since gaining regulatory approval in Australia to start human studies in mid-CY23. SDC-1801, a TYK2/JAK1 inhibitor targeting the autoimmune space, has reported a good safety profile to date and top-line data for the ongoing Phase Ia study are expected in Q2 CY24, a key catalyst for the company. The TYK2 class’s safety and efficacy has been validated by the likes of Sotyktu and TAK-279, and SDC-1801’s ...
- Emily Liu
Hybridan Small Cap Feast: 2 April 2024
2nd April 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objecti...
Hybridan Small Cap Feast - 28 Mar 24
28th March 2024 Happy Easter @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific inve...
Hybridan Small Cap Feast - 15 Mar 2024
15th March 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: Forward Partners Group (FWD.L) has left AIM following its acquisition by Molten Ventures (GROW.L) What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: Our daily digest of news from UK Small Caps If you wo...
Hybridan Small Cap Feast - 13 Mar 2024
13th March 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email with “unsubscribe me”. Hybridan Chefs Banquet Buffet*** ...
- Sean Conroy
Sareum Holdings - Positive clinical step forward in SDC-1801
Sareum Holdings has announced positive clinical progression for SDC-1801, its lead asset and novel TYK2/JAK1 inhibitor targeting the autoimmune space (with an initial focus on psoriasis). Preliminary data from the single ascending dose (SAD) study (part 1) and the food effects study (part 3), from its ongoing Phase Ia trial (in healthy volunteers) for SDC-1801, indicated a favourable safety profile and were supportive of once-daily oral dosing. The multiple ascending dose (MAD) arm continues to ...
- Emily Liu
Hybridan Research: 15/02/2024: Sareum Holdings PLC: Completion of sing...
Sareum today announced the completion of the single ascending dose (SAD) part and the food effect study of its Phase 1a clinical trial for the lead programme SDC-1801. The Phase 1a trial is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral formulation of SDC-1801 in healthy subjects (trial ID ACTRN12623000416695p). These preliminary results indicate that SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious ad...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.